Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

İhsan Ekin Demir

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8241-1871; OpenAlex author ID A5088890575. Sources: OpenAlex.

Their work

Papers
66 (first author 8, last author 20)
Trials
0
Grants
0
Labs led
1
Collaborators
185
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 5 papers · 2018: 4 papers · 2019: 2 papers · 2020: 6 papers · 2021: 9 papers · 2022: 4 papers · 2023: 2 papers · 2024: 7 papers · 2025: 11 papers · 2026: 8 papers

Papers 50 of 66

  1. Prognostic implications of superior mesenteric vein/portal vein resection and histologic venous invasion in BR/LA PDAC after neoadjuvant therapy. Co-author DOI 10.1007/s00423-026-04145-9↗
  2. Heterogeneity in the management of patients with locally advanced pancreatic cancer: current surgeons' perspective and lessons for the future. Last author DOI 10.1007/s13304-026-02651-5↗
  3. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Last author DOI 10.1016/j.ccell.2026.07.014↗
  4. Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. Co-author DOI 10.1016/j.xcrm.2025.102546↗
  5. Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41388-026-04026-x↗
  6. Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism. Co-author DOI 10.1136/gutjnl-2025-337316↗
  7. The substance P/ Neurokinin-1 receptor signaling drives perineural invasion in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3389/fcell.2026.1876023↗
  8. Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers18071131↗
  9. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions. Co-author DOI 10.1002/ueg2.70118↗
  10. Pancreatic cancer cells survive in the neural niche during neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2025.217894↗
  11. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Last author DOI 10.1016/j.ccell.2025.09.003↗
  12. Pancreatic cancer cells infiltrate nerves through TGFbeta1-driven perineural epithelial-to-mesenchymal-like transdifferentiation. Co-author DOI 10.1016/j.neo.2025.101126↗
  13. Neural invasion severity is a strong predictor of local recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.109018↗
  14. Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology. Co-author DOI 10.1016/j.tranon.2025.102535↗
  15. Extracellular vesicles from pancreatic cancer and its tumour microenvironment promote increased Schwann cell migration. Co-author DOI 10.1038/s41416-024-02915-0↗
  16. Neural crossroads of pancreatic cancer: how nociceptors drive tumor progression and immune evasion. Last author DOI 10.1038/s41422-025-01124-5↗
  17. TRANSCRIPTOMIC ANALYSIS OF THE RELATIONSHIP BETWEEN PANCREATIC DUCTAL ADENOCARCINOMA STROMAL SUBTYPES AND NEURAL INVASION First author DOI 10.1101/2025.01.13.632859↗
  18. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
  19. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  20. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping. Co-author DOI 10.1002/2056-4538.12377↗
  21. DOTA-Based Plectin-1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human Tissue. Co-author DOI 10.1002/anie.202318485↗
  22. Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunother… Last author DOI 10.1002/cac2.12496↗
  23. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Last author DOI 10.1007/s00423-024-03570-y↗
  24. Correlation of intratumoral mast cell quantity with psychosocial distress in patients with pancreatic cancer: the PancStress study. Last author DOI 10.1038/s41598-024-77010-8↗
  25. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. Last author DOI 10.1093/bjsopen/zrad125↗
  26. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2024.1378190↗
  27. Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. Last author DOI 10.1097/as9.0000000000000302↗
  28. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Last author DOI 10.1172/jci166333↗
  29. Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery. Last author DOI 10.1159/000519755↗
  30. The Effect of Celiac Neurolysis and Splanchnicectomy on Survival in Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Last author DOI 10.1159/000520456↗
  31. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  32. Regulatory T Cells in Pancreatic Cancer: Of Mice and Men. Last author DOI 10.3390/cancers14194582↗
  33. Innervated mouse pancreas organoids as an ex vivo model to study pancreatic neuropathy in pancreatic cancer. Last author DOI 10.1016/j.xpro.2021.100935↗
  34. Chemokines: the (un)usual suspects in pancreatic cancer neural invasion. Co-author DOI 10.1038/s41575-020-0329-1↗
  35. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  36. TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer. Co-author DOI 10.1084/jem.20210911↗
  37. TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-4125↗
  38. Effects of COVID-19 Pandemic on the Treatment of Pancreatic Cancer: A Perspective from Central Europe. First author DOI 10.1159/000513157↗
  39. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00808-4↗
  40. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma. Co-author DOI 10.14670/hh-18-332↗
  41. Patterns and Relevance of Langerhans Islet Invasion in Pancreatic Cancer. Last author DOI 10.3390/cancers13020249↗
  42. Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? Last author DOI 10.1007/s00423-020-01946-4↗
  43. Microenvironmental Determinants of Pancreatic Cancer. Co-author DOI 10.1152/physrev.00042.2019↗
  44. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Last author DOI 10.1158/1078-0432.ccr-19-1864↗
  45. Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation. Last author DOI 10.1186/s13046-020-01796-4↗
  46. Future directions of neoadjuvant therapy in pancreatic cancer. Last author DOI 10.18632/oncoscience.506↗
  47. Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. Co-author DOI 10.3390/cancers12082274↗
  48. Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling. Co-author DOI 10.1002/1878-0261.12463↗
  49. Venous resection during pancreatectomy for pancreatic cancer: a systematic review. First author DOI 10.21037/tgh.2019.06.01↗
  50. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. First author DOI 10.1002/bjs5.46↗

Closest collaborators

The 25 strongest of 185 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Helmut Friess · 27 shared papers, 2011–2026 · strength 4.83
  2. Guralp Onur Ceyhan · 38 shared papers, 2011–2026 · strength 4.77
  3. Carmen Mota Reyes · 22 shared papers, 2017–2026 · strength 3.85
  4. Helmut Frieß · 21 shared papers, 2013–2025 · strength 2.31
  5. Okan Safak · 10 shared papers, 2020–2025 · strength 1.59
  6. Ilaria Pergolini · 8 shared papers, 2021–2026 · strength 1.51
  7. Alexander Muckenhuber · 10 shared papers, 2017–2025 · strength 1.46
  8. Stephan Schorn · 13 shared papers, 2013–2025 · strength 1.40
  9. Rüdiger Göß · 8 shared papers, 2017–2025 · strength 1.29
  10. Florian Scheufele · 7 shared papers, 2017–2026 · strength 1.23
  11. Hana Algül · 10 shared papers, 2013–2026 · strength 1.22
  12. Kaan Çifcibaşı · 6 shared papers, 2022–2026 · strength 1.21
  13. Dieter Saur · 7 shared papers, 2022–2026 · strength 1.18
  14. Lei Ren · 7 shared papers, 2020–2026 · strength 1.15
  15. Roland Michael Schmid · 8 shared papers, 2021–2025 · strength 1.12
  16. Roland Rad · 6 shared papers, 2022–2026 · strength 0.96
  17. Alexander Novotny · 5 shared papers, 2021–2026 · strength 0.95
  18. Linhan Ye · 6 shared papers, 2021–2025 · strength 0.90
  19. Kıvanç Görgülü · 6 shared papers, 2021–2026 · strength 0.89
  20. Maximilian Reichert · 6 shared papers, 2021–2025 · strength 0.87
  21. Marina Lesina · 6 shared papers, 2017–2026 · strength 0.81
  22. Achim Krüger · 6 shared papers, 2017–2026 · strength 0.77
  23. Anna Melissa Schlitter · 6 shared papers, 2017–2025 · strength 0.70
  24. Wilko Weichert · 6 shared papers, 2017–2025 · strength 0.67
  25. Marc Eric Martignoni · 3 shared papers, 2023–2026 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.